| h-319955cb66 | Targeting Synaptic Vesicle Release Machinery to Block Tau Exocytosis | 0.63 | 0.65 | SNAP25 | proposed | 2026-04-22 | SDA-2026-04-04-gap-tau-prion-spreading |
| h-652a706ec8 | Restoration of V-ATPase function reverses lysosomal acidification defect in AD n | 0.63 | 0.68 | ATP6V1A, ATP6V0C | proposed | 2026-04-22 | SDA-2026-04-04-gap-lysosomal-cathepsin-ad |
| h-4a83434d37 | Epigenetic Bivalency at CDKN2A Locus Distinguishes Senescent from Activated Micr | 0.63 | 0.72 | CDKN2A, H3K9me3, DREAM complex (LIN9, LIN37, RBL2) | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-6af4ba5f |
| h-d44394f958 | Steric Occlusion of G3BP1 Oligomerization Interface | 0.63 | 0.68 | G3BP1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041423-2d1db50c |
| h-c883a9eb10 | Combine Anti-AQP4 Autoimmunity Control with Astrocyte-Endfoot Repair in NMOSD | 0.63 | 0.60 | AQP4, IL6R, CD19, C5 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2 |
| h-7eea3c3380 | Treat Glymphatic Failure by Coupling AQP4-Targeted Therapy to Sleep/Noradrenergi | 0.63 | 0.58 | AQP4, ADRA2, LC | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2 |
| h-815e1cb9c9 | Hierarchical Phase Separation with Scaffold Cores | 0.63 | 0.62 | Ddx6, 4E-T, FMRP, TIA1, G3BP1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041428-53b81741 |
| h-05b40151e8 | Partial OSK Reprogramming Reverses Epigenetic Aging Without Dedifferentiation | 0.63 | 0.75 | Oct4; Sox2; Klf4; TP53 | proposed | 2026-04-21 | SDA-2026-04-10-gap-20260410-091440 |
| h-9d22b570 | Programmable Neuronal Circuit Repair via Epigenetic CRISPR | 0.63 | 0.30 | NURR1, PITX3, neuronal identity transcription factors | proposed | 2026-04-03 | SDA-2026-04-03-gap-crispr-neurodegeneration-20260402 |
| h-0d576989 | Selective Cholinergic Protection via APP Pathway Modulation | 0.63 | 0.65 | APP | proposed | 2026-04-04 | SDA-BIOMNI-CLINICAL-b7a71edd |
| SDA-2026-04-16-hyp-9 | APOE4-Driven Astrocyte Senescence as Primary Target | 0.63 | 0.46 | APOE,CDKN1A,BCL2L1 | proposed | 2026-04-16 | SDA-2026-04-04-gap-senescent-clearance-neuro |
| h-40ad6ac6 | Gut-Brain Axis M-Cell Modulation | 0.63 | 0.56 | GP2, SPIB | proposed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| h-e23f05fb | Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring | 0.63 | 0.30 | Disease-causing mutations with integrated reporters | proposed | 2026-04-03 | SDA-2026-04-03-gap-crispr-neurodegeneration-20260402 |
| h-trem2-883b6abd | TREM2 Antagonism in Late-Stage Tauopathy — Reducing Neuroinflammatory Amplificat | 0.63 | 0.58 | TREM2 | proposed | 2026-04-05 | SDA-2026-04-02-gap-001 |
| h-4a31c1e0 | Quantum Coherence Disruption in Cellular Communication | 0.63 | 0.57 | TUBB3 | debated | 2026-04-02 | sda-2026-04-01-gap-009 |
| h-1e70cd6400 | Rutin stabilizes a non-nucleating tau conformer through direct MAPT repeat-domai | 0.63 | 0.55 | MAPT | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-085530-9015d285-debate |
| h-065716ca | TREM2 Super-Agonist Induction of DAM Program | 0.63 | 0.22 | TREM2 | proposed | 2026-04-21 | SDA-2026-04-16-gap-20260416-220243 |
| h-6f1e8d32 | Cardiovascular-Neuroinflammatory Dual Targeting | 0.63 | 0.50 | TNF/IL6 | debated | 2026-04-04 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| h-a635d4e5 | Default Mode Network Circuit Stabilization | 0.63 | 0.55 | VIP | proposed | 2026-04-04 | SDA-2026-04-03-26abc5e5f9f2 |
| h-bb29eefbe7 | RNA-binding protein condensate maturation from reversible phase separation to am | 0.63 | 0.62 | FUS | proposed | 2026-04-28 | 52661eaf-79f8-4647-8f48-3389f5af4d59 |
| h-f90159a23e | mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inf | 0.63 | 0.62 | FUS | proposed | 2026-04-28 | 687fb884-6d31-47c3-a83f-074bad980db6 |
| h-fa69d9c90d | APOE ε4-driven microglial lipid handling as proximal driver in Non-Neuronal Tran | 0.63 | 0.62 | RNA- | proposed | 2026-04-28 | db9a224d-3ebb-429c-8f02-b703d71ca211 |
| h-f5a04f2c9c | m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetic | 0.63 | 0.62 | m6A | proposed | 2026-04-28 | b7f886d9-da3f-4e0d-a8a8-9c262e268796 |
| h-8f6fd1d64f | CCL2-CCR2 myeloid signaling as a selective driver of fast-fatigable motor-neuron | 0.63 | 0.62 | CCL2-CCR2 | proposed | 2026-04-28 | f7f8019f-08f6-428b-adff-85e8ea202b60 |
| h-b43242fa6b | RNA-binding protein condensate maturation from reversible phase separation to am | 0.63 | 0.62 | TDP-43 | proposed | 2026-04-28 | 0ed3c364-07fd-4620-8e90-8bd33c14e370 |
| h-9192d8f97e | PD genetic aging variants accelerating cell-type-specific epigenetic clock traje | 0.63 | 0.62 | PD- | proposed | 2026-04-28 | bf5094c7-8ae0-4331-9871-d6f3078387c5 |
| h-54c3df2f08 | early PD proteogenomic hubs that are both causal enough and accessible enough to | 0.63 | 0.62 | SNCA | proposed | 2026-04-28 | 8ec36980-febb-4093-a5a1-387ea5768480 |
| h-1f7e4943f9 | VEGF-family genetic control of vascular-neuronal coupling in vulnerable hippocam | 0.63 | 0.62 | VEGF | proposed | 2026-04-28 | a7f528aa-20c4-409d-a8c3-e2662850e63d |
| h-aad6475a2e | DPP6-linked neuronal regulatory networks controlling synaptic excitability and c | 0.63 | 0.62 | DPP6 | proposed | 2026-04-28 | 457c5bc3-21d8-42a3-bb99-b0fc6f3f9554 |
| h-13c4be94d5 | sex-divergent microglial activation states and X-linked immune escape genes as p | 0.63 | 0.62 | amyloid-beta | proposed | 2026-04-28 | dfb32151-9c40-452d-8063-0c57bae5c3d6 |
| h-efbedb10 | Peripheral-to-Central Inflammation Circuit Breaker | 0.63 | 0.61 | IL1B | proposed | 2026-04-16 | SDA-2026-04-16-gap-bbb-tjp-20260416041707 |
| h_seaad_001 | Microglial TREM2 downregulation impairs damage-associated response in late-stage | 0.63 | 0.82 | TREM2 | promoted | 2026-04-04 | SDA-2026-04-04-analysis_sea_ad_001 |
| h-var-a065d9bdf2 | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | 0.63 | 0.72 | TREM2 | archived | 2026-04-07 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-SDA-2026-04-26-gap | Integrated Blood Panel of sPDGFRβ, sTM, and Circulating microRNA-320 Predicts Pr | 0.62 | 0.40 | PDGFRβ, THBD, mir320a/b/c | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260426-002803 |
| h-SDA-2026-04-26-gap | Ribosome Stalling and Collision-Induced Translational Repression | 0.62 | 0.52 | GBA mRNA; ZNF598, GIGYF2, RQC components | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260412-094853-199f4f1b |
| h-SDA-2026-04-26-gap | RNA-Binding Protein Sequestration and 3′UTR Dysregulation | 0.62 | 0.52 | ELAVL1 (HuR), FMR1 (FMRP), TARDBP (TDP-43); GW182 (TNRC6A) | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260412-094853-199f4f1b |
| h-SDA-2026-04-26-gap | Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline | 0.62 | 0.40 | PDGFRβ | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260426-002803 |
| h-97c6046c6b | H7: Aberrant RNA Template Switching Converts Granules to Aggregation Prone | 0.62 | 0.60 | G3BP1, DDX3X, DDX6 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041428-4c4414ad |
| h-var-fd2fd0825b | APOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma Oscillation Restorati | 0.62 | 0.41 | APOE/PVALB | proposed | 2026-04-16 | |
| h-5dbfd3aa | Heat Shock Protein 70 Disaggregase Amplification | 0.62 | 0.70 | HSPA1A | debated | 2026-04-02 | sda-2026-04-01-gap-006 |
| h-513a633f | Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics | 0.62 | 0.45 | ANXA1 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-691b42f1 |
| h-5a752d3628 | Galectin-3 deletion attenuates NLRP3 inflammasome activation downstream of lysos | 0.62 | 0.70 | LGALS3 | proposed | 2026-04-22 | SDA-2026-04-04-gap-lysosomal-cathepsin-ad |
| SDA-2026-04-16-hyp-4 | Autophagy-Senescence Axis Therapeutic Window | 0.62 | 0.70 | ATG7,BCL2,BCL2L1 | promoted | 2026-04-16 | SDA-2026-04-04-gap-senescent-clearance-neuro |
| h-ebea83c410 | ATF4-DDIT3 stress signaling indirectly represses MAPT transcription during prote | 0.62 | 0.59 | ATF4 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-083749-7d0cea3d-debate |
| h-dca3e907 | Serine/Arginine-Rich Protein Kinase Modulation | 0.62 | 0.40 | SRPK1 | debated | 2026-04-02 | sda-2026-04-01-gap-006 |
| h-d9604ebf | Myelin Sulfatide Restoration | 0.62 | 0.70 | GAL3ST1 | promoted | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-e5a1c16b | TFEB-PGC1α Mitochondrial-Lysosomal Decoupling | 0.62 | 0.50 | TFEB | proposed | 2026-04-03 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-a87702b6 | Cholesterol-CRISPR Convergence Therapy for Neurodegeneration | 0.62 | 0.40 | HMGCR, LDLR, APOE regulatory regions | proposed | 2026-04-03 | SDA-2026-04-03-gap-crispr-neurodegeneration-20260402 |
| h-var-f4b4d4de63 | Optogenetic viral vector delivery via tFUS-mediated blood-brain barrier opening | 0.62 | 0.65 | PVALB | proposed | 2026-04-07 | SDA-2026-04-03-26abc5e5f9f2 |
| h-6e76ba3638 | TOM/TIM Complex Disruption Triggering Mitochondrial Integrated Stress Response ( | 0.62 | 0.55 | TOMM40, TOMM70, CLPP | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062141-739c7f1c |